Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-8577 vs Solifenacin/Mirabegron in Overactive Bladder
NCT03106623Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ONO-8577 in overactive bladder (OAB) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Change From Baseline to Week 4 in Mean Number of Micturitions Per 24 Hours. Started Apr 2017; status: completed.
02
Drugs
ONO-8577
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03106623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106623.